Effect of SLCO1B1 Polymorphisms on High‐Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma
Authors:
Open Access
- 22 September 2020
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 14 (1) , 343-353
Abstract
High‐dose (HD) methotrexate (MTX) is a critical component of treatment for hematologic malignancies in children and young adults. Therapeutic drug monitoring is necessary due to substantial interindividual variation in MTX clearance. Common function‐altering polymorphisms in SLCO1B1 (encodes OATP1B1, which transports MTX) may contribute to clearance variability. We performed pharmacokinetic modeling using data for 106 children and young adults treated with HD MTX for hematologic malignancies; of 396 total courses of HD MTX, 360 consisted of 5 g/m2 over 24 hours. We evaluated the contribution of clinical covariates and SLCO1B1 genotype (388A>G and 521T>C) to MTX clearance variability. Of the clinical covariates studied, patient weight improved the pharmacokinetic model most significantly (P < 0.001). The addition of the SLCO1B1 variants individually further improved the model (P < 0.05 for each). An interaction between these variants was suggested when both were included (P = 0.017). SLCO1B1 genotype should be considered in efforts to personalize HD MTX dosing.Keywords
This publication has 36 references indexed in Scilit:
- Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunitiesBritish Journal of Haematology, 2019
- Preventing and Managing Toxicities of High-Dose MethotrexateThe Oncologist, 2016
- Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232Journal of Clinical Oncology, 2016
- Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology GroupBritish Journal of Haematology, 2013
- Genome-wide study of methotrexate clearance replicates SLCO1B1Blood, 2013
- Polymorphisms of the SLCO1B1 gene predict methotrexate‐related toxicity in childhood acute lymphoblastic leukemiaPediatric Blood & Cancer, 2011
- Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical EffectsJournal of Clinical Oncology, 2009
- Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variablesLeukemia Research, 2000
- Clinical and Pharmacokinetic Risk Factors for High-dose Methotrexate-induced Toxicity in Children with Acute Lymphoblastic Leukemia: A Logistic Regression AnalysisActa Oncologica, 1998
- Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic LeukemiaNew England Journal of Medicine, 1986